Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus

Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Eiji, Hayashi, Takanori, Akaza, Mao, Hisatomi, Yukiko, Hikichi, Masahiro, Fujii, Takuma, Utsumi, Toshiaki, Harada, Nobuhiro, Shimono, Yohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530388/
https://www.ncbi.nlm.nih.gov/pubmed/32810922
http://dx.doi.org/10.1002/2211-5463.12956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530388/
https://www.ncbi.nlm.nih.gov/pubmed/32810922
http://dx.doi.org/10.1002/2211-5463.12956

Ejemplares similares